$RCKT

Rocket Companies, Inc. Stock 12‑Month Price Target Cut to $16.54, Implies 44% Upside

Rocket Companies, Inc.'s average stock price target was reduced by analysts from $16.77 to $16.54, with a range of $12.5 to $21. This implies a 44% upside from the Oct. 9 closing price. The consensus rating remains 'Buy' among 18 analysts, with 10 Buys, 8 Holds, and 0 Sells.

Original reporting
Published Oct 12, 2026, 1:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 1:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Rocket Companies, Inc. Stock 12‑Month Price Target Cut to $16.54, Implies 44% Upside — source image
Decision brief

The 30-second read

$RCKTNeutralLow
01

Why it matters

The modest target reduction suggests a slight downgrade in growth expectations, but the still‑high upside may keep the stock attractive to long‑term investors.

02

Market read

Analyst target adjustment offers a small trading signal; limited broader market effect.

03

What to watch

Potential upside from upcoming earnings or new loan‑originations not reflected in the target.

Relevance 5/10Novelty 5/10Timing: today

Background

Rocket Companies provides mortgage‑related services; analyst price targets reflect expectations for earnings and loan growth.

Company-level read

Ticker impact

$RCKTNeutralMedium confidence
Context

Analyst consensus price target for Rocket Companies was lowered to $16.54, implying ~44% upside from the current price.

Expected impact

possible modest pressure as investors reassess valuation, but upside remains attractive

Evidence & confidence

The new target is a primary disclosure but the magnitude is modest and the stock already trades near the prior target.

Market effects

Minor impact on mortgage‑finance sector as analysts adjust expectations.

U.S. equity market sees limited ripple.

Low

Counterpoint

The target cut may be over‑reacting to short‑term noise; the stock could still rally on broader housing demand.

Key entities

  • Rocket Companies, Inc.

    U.S. mortgage‑finance firm (ticker RCKT).

Related articles

$RCKTMed

Goldman Sachs Upgrades Rocket Pharmaceuticals (RCKT) to Neutral

Goldman Sachs upgraded Rocket Pharmaceuticals (RCKT) to Neutral, citing encouraging clinical updates on its gene therapy candidate RP-A501. The company remains unprofitable with no revenue, but its market cap of $284M reflects growth expectations. RCKT's GF Score is 35/100, showing mixed fundamentals. Insiders have sold shares, while some institutional investors hold positions.

$RCKTHigh

Why is Rocket Pharmaceuticals stock up 3% today?

Rocket Pharmaceuticals (RCKT) rose 2.8% after Goldman Sachs upgraded it to Neutral with a $4.00 price target, citing positive clinical data for RP-A501. Other analysts maintained bullish ratings, while some lowered targets due to long timelines. The company secured a $150M credit facility. The move was company-specific, as broader markets were down.

$RCKTMedAI 8/10

Rocket Pharmaceuticals bags $150 million as it pushes pivotal Danon disease study

Rocket Pharmaceuticals secured up to $150 million in financing from Hercules Capital, including an initial $35 million. The funds will support a pivotal Phase 2 study for its gene therapy candidate RP-A501 for Danon disease and broader cardiovascular pipeline development. The company reported $283.7 million in cash as of June 30, 2026, and expects the financing to extend its cash runway.